作者: Otilia Leon , Marianne G. Guren , Calin Radu , Adalsteinn Gunnlaugsson , Anders Johnsson
DOI: 10.1016/J.EJCA.2015.08.029
关键词:
摘要: 5-fluorouracil (5FU) and mitomycin C (MMC)-based chemoradiotherapy (CRT) is standard treatment for anal squamous cell carcinoma. In this phase I study cetuximab was added the primary aim to determine maximum tolerated dose (MTD) of 5FU MMC in combination.